Takeda Pharmaceutical

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present four company-sponsored abstracts at the Tandem Transplantation & Cellular Therapy Meetings in Salt Lake City, Utah, and the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Lisbon, Portugal between April 23 and 26, 2022. The exploratory data presented at both meetings provide an opportunity to share important new analyses of LIVTENCI

Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY™ (Maribavir) Had Reductions in Hospitalization Rates and Length of Hospital Stay

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for Nuvaxovid® Intramuscular Injection (Nuvaxovid), a novel recombinant protein-based COVID-19 vaccine, for primary and booster immunization in individuals aged 18 and older. Novavax licensed and transferred its manufacturing technologies to enable Takeda to develop and manufacture the

Takeda Announces Approval of Nuvaxovid® COVID-19 Vaccine for Primary and Booster Immunization in Japan

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced TAKHZYRO® (lanadelumab-flyo) injection single-dose prefilled syringe is now available in the U.S. to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.1 HAE is a rare genetic disease that results in recurrent attacks of edema (swelling) in various parts of the body, which can be burdensome, debilitating and potentially life-threatening.2,3,4 Approved by the U.S. F

Takeda's TAKHZYRO® (lanadelumab-flyo) Prefilled Syringe Now Available for People With Hereditary Angioedema (HAE) Ages 12 Years and Older in the United States

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today provided an update on the status and announced the completion of the acquisition of its own shares, which has been carried out pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act of Japan, based on the resolution of the Board of Directors' meeting held on October 28, 2021. Details of the acquisition of shares is below

Takeda Announces Completion of Acquisition of Own Shares

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the Phase 3 SHP643-301 study (NCT04070326) evaluating the safety profile and pharmacokinetics (PK) of TAKHZYRO® (lanadelumab) in patients 2 to

Takeda's TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Children Ages 2 to

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda and the New York Academy of Sciences announced the winners of the fourth Innovators in Science Award.

Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award Winners

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) for TAKHZYRO® (lanadelumab) subcutaneous injection 300mg syringes for prophylaxis against acute attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older in Japan.1 Hereditary angioedema (HAE) is a rare genetic disorder that results in recurring attacks of oedema – swelling – in va

Takeda's TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)

Toyota Motor

Japan has the world's third-largest economy, which has started to rebound from the pandemic. The Japanese economy expanded at a 5.4% annualized rate in the fourth quarter of 2021.

3 Japanese Stocks to Diversify Your Portfolio

Takeda Pharmaceutical ( TAK , Financial) is Japan's largest R&D-focused biopharma company. Founded in 1781, this is an established company with a global presence.

Takeda Pharma: A Japanese Dividend Powerhouse

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--AAAAI Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients

Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients

Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of Alofisel (darvadstrocel). The study demonstrated clinical remission in 65% of patients in both cohorts evaluated at six months, with Crohn's disease (CD) and complex perianal fistulas.

Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-Months

OSAKA, Japan & CAMBRIDGE, Massachusetts--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the first six-month interim analysis results from INSPIRE, in which clinical remission* was observed in 65% of patients in both cohorts who were evaluated at 6 months.1 INSPIRE is a European, observational, multicenter, post-approval, open-enrollment study (EUPAS24267) evaluating the real-world effectiveness and safety of Alofisel (darvadstrocel) in patients with Crohn's disease (CD) and complex

Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analysis Consistent with the Pivotal Clinical ADMIRE-CD Study1,2

SAN DIEGO--(BUSINESS WIRE)--National Resilience, Inc. (Resilience), a technology-focused manufacturing company dedicated to broadening access to complex medicines, today announced a manufacturing services agreement with Takeda's Plasma-Derived Therapies Business Unit. As part of the agreement, Resilience will focus on supporting the development and manufacture of multiple products in Takeda's plasma-derived medicines portfolio out of its facility in Mississauga, Ontario. “I'm proud to establish

Resilience Establishes Multi-Product Development and Manufacturing Collaboration with Takeda's Plasma-Derived Therapies Business Unit

Weber

Takeda Pharmaceutical Company Limited (TAK) CEO Christophe Weber on Q3 2022 Results - Earnings Call Transcript

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for the third quarter of its fiscal year 2021 (period ended December 31, 2021) driven by robust topline growth of its 14 global brands. Based on the strong third-quarter results and business momentum, the company upgraded forecasts for full fiscal year revenue, reported and core operating profit, reported and core EPS and free cash flow. Takeda remains positioned for long-term business growth wi

Takeda Delivers Strong Third Quarter FY2021 Results and Raises Full-Year Forecast Reflecting Strong Momentum

The FDA has approved Takeda Pharmaceutical Co Ltd's TAK Vonvendi [von Willebrand factor (Recombinant)] for routine prophylaxis to reduce the frequency of bleeding episodes in Type 3 von Willebrand disease (VWD) receiving on-demand therapy. [ALERT] Nic Chahine shares his Bear Market Beating options trading strategy.

FDA Approves Takeda's Vonvendi As Prophylactic Treatment In Bleeding Disorder

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food & Drug Administration (FDA) approved VONVENDI® [von Willebrand factor (Recombinant)] for routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe Type 3 von Willebrand disease (VWD) receiving on-demand therapy. VONVENDI is the only recombinant von Willebrand factor (VWF) replacement therapy, and the first and only treatmen

FDA Approves Prophylactic Treatment with VONVENDI® [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD)

Viatris

These two dividend-paying pharma stocks ought to be top performers in 2022.

2 Dirt-Cheap Value Stocks to Buy Now

The T. Rowe Price Japan Fund (Trades, Portfolio), part of Baltimore-based T.

T. Rowe Price Japan Dumps Takeda Holding in 4th Quarter

Amgen

PetMed Express

Looking for a healthcare stock that will pay you to own it? Here are three suggestions.

3 Healthcare Stocks With High Dividends

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it was one of only 11 companies to achieve global Top Employer® certification for 2022, marking the fifth consecutive year that it has been recognized for outstanding people policies and practices worldwide. In addition to the global certification, Takeda is also recognized as a Top Employer across four regions and 39 countries, reinforcing its steadfast co

Takeda Named Global Top Employer for Fifth Consecutive Year

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today confirmed the company is positioned for growth in the mid- and long-term with the potential to deliver incremental revenue growth and additional upside potential through FY2030. Presenting at the 40th Annual J.P. Morgan Healthcare Conference, Christophe Weber, Takeda's President and Chief Executive Officer, reinforced the mid-term revenue growth potential of its 14 global

Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40th Annual J.P. Morgan Healthcare Conference

OSAKA, Japan & LONDON--(BUSINESS WIRE)--Takeda exercised its option to acquire Adaptate Biotherapeutics, adding a gamma delta T-cell engager platform to Takeda's immuno-oncology portfolio.

Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors

Dynex Capital

Annaly Capital

Oppenheimer Holdings

These four stocks are all trading below their book value, making it likely that their names are showing up on the value screens of large institutional investors. Since each one trades on the New York Stock Exchange, plenty of information is available for those who want to go into depth on them in order to determine whether they could be good investments.

4 'Below Book Value' Stocks

Takeda Pharmaceutical Co Ltd (NYSE: TAK) received a Complete Response Letter (CRL) from the FDA for its marketing application for TAK-721 (budesonide oral suspension) for eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus. The CRL indicates the FDA has completed its review of the TAK-721 NDA and determined that it cannot be approved in its present form.

News for Takeda Pharmaceutical Stock (TAK)